Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gisle Langslet

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Journal of Clinical Lipidology|October 2, 2017
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemiaJoep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
The Journal of Clinical Endocrinology and Metabolism|June 6, 2019
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated StatinDirk Müller-Wieland, Daniel J Rader, Patrick M Moriarty, et al.
Journal of the American College of Cardiology|October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With HypercholesterolemiaMichael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
Journal of Clinical Lipidology|February 4, 2018
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemiaMerel L Hartgers, Joep C Defesche, Gisle Langslet, et al.
Journal of Clinical Lipidology|October 2, 2013
Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemiaD Meeike Kusters, Barbarba A Hutten, Brian W McCrindle, et al.
Journal of Clinical Lipidology|April 4, 2018
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FHKirsten B Holven, Ingunn Narverud, Jeanine Roeters van Lennep, et al.
Circulation|November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trialMichael J Koren, Robert P Giugliano, Frederick J Raal, et al.
Lancet (London, England)|March 7, 2015
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 studyJohn J P Kastelein, Joost Besseling, Sukrut Shah, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Journal of Clinical Lipidology|October 2, 2017
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemiaJoep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
The Journal of Clinical Endocrinology and Metabolism|June 6, 2019
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated StatinDirk Müller-Wieland, Daniel J Rader, Patrick M Moriarty, et al.
Journal of the American College of Cardiology|October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With HypercholesterolemiaMichael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
Journal of Clinical Lipidology|February 4, 2018
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemiaMerel L Hartgers, Joep C Defesche, Gisle Langslet, et al.
Journal of Clinical Lipidology|October 2, 2013
Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemiaD Meeike Kusters, Barbarba A Hutten, Brian W McCrindle, et al.
Journal of Clinical Lipidology|April 4, 2018
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FHKirsten B Holven, Ingunn Narverud, Jeanine Roeters van Lennep, et al.
Circulation|November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trialMichael J Koren, Robert P Giugliano, Frederick J Raal, et al.
Lancet (London, England)|March 7, 2015
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 studyJohn J P Kastelein, Joost Besseling, Sukrut Shah, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Pageof 6